Pulmonary arterial hypertension and benfluorex: 5 case reports

Therapie

Volumn 66, Issue 2, 2011, Pages 135-138

  Bondon Guitton, Emmanuelle ^a,b   Prévôt, Grégoire ^c   Didier, Alain ^c   Montastruc, Jean Louis ^a,b,d  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Adverse drug reaction reporting systems; Benfluorex; Drug toxicity; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BENFLUOREX; BOSENTAN; FUROSEMIDE; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; MALE; OBESITY; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SLEEP APNEA SYNDROME;

EID: 79959358492     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2011018     Document Type: Article

References (29)

1. Noize P, Sauer M, Bruneval P, et al. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 2006; 20: 577-8 (Pubitemid 44762174)
2. Rafel Ribera J, Casañas Muñoz R, Anguera Ferrando N, et al. Valvular heart disease associated with benfluorex. Rev Esp Cardiol 2003; 56: 215-6 (Pubitemid 36305071)
3. Rappel des spécialités à base de benfluorex - Afssaps : Agence française de sécurité sanitaire des produits de santé. http://www.afssaps.fr/Infos-de-securite/Retraits-de- lots-et-de-produits/Rappel-des-specialites-a-base-de-benfluorex
4. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9
5. Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: periodic safety update reports for marketed drugs. Fed Regist 2004; 5551-2
6. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-8
7. Thiessard F, Roux E, Miremont-Salamé G, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986- 2001). Drug Saf 2005; 28: 731-40 (Pubitemid 41132459)
8. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23 (Pubitemid 17137857)
9. Bégaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588
10. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol 1997; 52: 423-7. (Pubitemid 27395640)
11. Mann R, Andrews E. Pharmacovigilance. Chichester: John Wiley and Sons; 2002
12. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-8
13. Atanassoff PG, Weiss BM, Schmid ER, et al. Pulmonary hypertension and dexfenfluramine. Lancet 1992; 339: 436
14. Roche N, Labrune S, Braun JM, et al. Pulmonary hypertension and dexfenfluramine. Lancet 1992; 339: 436-7
15. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16 (Pubitemid 26277950)
16. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res 2002; 3: 9
17. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54
18. Eddahibi S, Humbert M, Fadel E, et al. Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002; 121(suppl): 97S-98S (Pubitemid 34248379)
19. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-50 (Pubitemid 32995372)
20. Griffen L, AnchorsM. The "phen-pro" diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158: 1278-9 (Pubitemid 28252498)
21. Boutet K, Frachon I, Jobic Y, et al. Fenfluramine-like cardiovascular sideeffects of benfluorex. Eur Respir J 2009; 33: 684-8
22. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30
23. Li R, Serdula MK, Williamson DF, et al. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy. Int J Obes Relat Metab Disord 1999; 23: 926-8 (Pubitemid 29423934)
24. Dahl CF, Allen MR, Urie PM, et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008; 6: 34
25. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-41
26. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S (Pubitemid 38759712)
27. Frachon I, Etienne Y, Jobic Y, et al. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE 2010; 5(4): e10128
28. Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010 Dec; 19(12): 1256-62
29. Haute Autorité de Santé (HAS) Avis de la Commission de Transparence. Mediator 150 mg Comprimés enrobés. 10 mai 2006. http://www.has-sante.fr/portail/jcms/c-449292/mediator